In vivo selection of transplanted MGMT-transduced normal BM cells results in sustained hematologic improvement in nonmyeloablated β-thalassemic mice. (A) Cellulose acetate gel electrophoresis of red cell lysates from donor C57BL/6 (B6), recipient β-thalassemic (THAL), and untreated control and drug-treated β-thalassemic recipient animals 14 weeks (top row) and 21 weeks (bottom row) after transplantation with 7 ×106 MGMT-transduced, nucleated BM cells. The MGMT-transduced, donor B6 graft has the “single” hemoglobin pattern, while the recipient THAL has the “diffuse” pattern. Mouse identification numbers are shown at the top of each lane. (B) Wright-Giemsa–stained blood smears are shown for a representative control, untreated animal (left) and for a drug-treated animal that demonstrated in vivo selection of transduced cells (right). Original magnification, × 250.
